Cybin is trading at $12.52 (-10.70%) with no confirmed company-specific catalyst identified for September 18, 2026.
- The September 16 Morgan Stanley presentation discussed a potential fourth-quarter Phase 3 readout, but available coverage does not link it to today’s decline.
- Broader markets are modestly lower, while biotechnology is higher.
- Sector strength does not explain Cybin’s drop.